If you have been reading about RP-HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-20. Numbers and descriptions here follow the published literature rather than marketing material.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Contains two non-natural residues |
| Molecular formula | C38H49N9O5 | Free base form |
| Molecular weight | 711.85 g/mol | Calculated from formula |
| Primary target | GHS-R1a ghrelin receptor | Agonist activity |
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.
Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.
Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
== Life == John H. Reynolds was born (1923-04-03)April 3, 1923 in Cambridge, Massachusetts. He studied first at Harvard University and, after serving in the Navy during World War II, at the University of Chicago. There, he was influenced by his Ph.D. thesis advisor Mark Inghram and by two other famous physicists, Harold Urey and Enrico Fermi. He specialized in mass spectrometry and utilized this method to determine isotope ratios needed for the radiometric dating of geologically and cosmologically relevant samples. In 1950 he was appointed as professor to the University of California, Berkeley where he continued his research on isotope ratios in meteorites, leading to the discovery in 1960 that the Richardton meteorite and other meteorites had an excess of xenon-129, thought to be a result of the beta decay of iodine-129 in the early Solar System. He was helped by a new all-glass spectrometer that he had designed, which allowed gas samples to be run through it multiple times, helping to increase the odds of detection and alleviate the low sensitivity problems plaguing earlier attempts by other researchers on other meteorites. Unlike many scientific discoveries, the significance of the discovery was well and widely understood at the time. His improvement of potassium-argon dating was also adopted by several institutions. Reynolds was a Guggenheim Fellow for the academic years 1956–1957 and 1986–1987. He was elected to the National Academy of Sciences in 1968. He died of pneumonia on November 4, 2000, in Berkeley, California.
=== Mods === Mod tools for the Source 2 engine and Steam Workshop support for Half-Life: Alyx were released on May 15, 2020. Valve announced plans to release a new Hammer level editor for Source 2, and planned to release a partial Source 2 software development kit for the updated features later, with the focus at launch on shipping and supporting Alyx. In March 2023, fans released the "NoVR" mod, which allows Alyx to be played without a VR headset. This also allows Alyx to run on less powerful devices, such as the Steam Deck. Reviewers found the mod removed immediacy and that mouse-and-keyboard controls could not replicate the dexterity of VR controllers.
=== Psychiatric disorders === Valproate products are used to treat manic or mixed episodes of bipolar disorder. A 2016 systematic review compared the efficacy of valproate as an add-on for people with schizophrenia:
When H+ ions accumulate in the muscles causing the blood pH level to reach low levels, temporary muscle fatigue results. Another limitation of the lactic acid system that relates to its anaerobic quality is that only a few moles of ATP can be resynthesized from the breakdown of sugar. This system cannot be relied on for extended periods of time. The lactic acid system, like the ATP-CP system, is important primarily because it provides a rapid supply of ATP energy. For example, exercises that are performed at maximum rates for between 1 and 3 minutes depend heavily upon the lactic acid system. In activities such as running 1500 meters or a mile, the lactic acid system is used predominantly for the "kick" at the end of the race.
Sources: en.wikipedia.org
== Treatment == Treatment of diving barotrauma depends on the symptoms, which depend on the affected tissues. Lung over-pressure injury may require a chest drain to remove air from the pleura or mediastinum. Recompression with hyperbaric oxygen therapy is the definitive treatment for arterial gas embolism, as the raised pressure reduces bubble size, the reduced blood inert gas concentration may accelerate inert gas solution, and high oxygen partial pressure helps oxygenate tissues compromised by the emboli. Care must be taken when recompressing to avoid a tension pneumothorax. Barotraumas that do not involve gas in the tissues are generally treated according to severity and symptoms for similar trauma from other causes.
=== Polycythemia in adults === Different diseases or conditions can cause polycythemia in adults. These processes are discussed in more detail in their respective sections below. Relative polycythemia, also known as pseudopolycythemia, is not a true increase in the number of red blood cells or hemoglobin in the blood, but rather an elevated laboratory finding caused by reduced blood plasma (hypovolemia, cf. dehydration). Relative polycythemia is often caused by loss of body fluids, such as through burns, dehydration, and stress. A specific type of relative polycythemia is Gaisböck syndrome; in this syndrome, primarily occurring in obese men, hypertension causes a reduction in plasma volume, resulting in (amongst other changes) a relative increase in red blood cell count. If relative polycythemia is deemed unlikely because the patient has no other signs of hemoconcentration and has sustained polycythemia without clear loss of body fluids, the patient likely has absolute or true polycythemia. Absolute or true polycythemia (also erythrocytosis) can be split into two categories:
An arterial embolism is caused by one or more emboli getting stuck in an artery and blocking blood flow, causing ischemia, possibly resulting in infarction with tissue death (necrosis). Individuals with arterial thrombosis or embolism often develop collateral circulation to compensate for the loss of arterial flow. However, it takes time for sufficient collateral circulation to develop, making affected areas more vulnerable for sudden occlusion by embolisation than for e.g. gradual occlusion as in atherosclerosis.
Sources: en.wikipedia.org
Among the Buddhists there was a Tocharian (Tho-gar) king called Men-dre, or Polosi, or Ānandavarmā. He had the caves painted by restorers and painters: Mitradatta; Naravāhanadatta from the lands of the "naked ones" (Niganthas); Priyaratna from Romakam (Byzantine Empire); and other experts in restoration. The king of the Rgya-ser and King Men-dre's bodies were taken by Amitābha and he went to the land of bliss. When the son of the great king of Rgya-ser came to the fort of Mir-li, thanks to the power of prayer, all the "naked ones" (Niganthas) were killed by the followers of Kālacakra, and all of the Buddhist caves were restored. According to Sam van Schaik, "Mendre" could be the Indo-Greek king Menander, or the mythical king Manadhatṛ of Buddhist sources; "Polosi" could be a Chinese abbreviation for king Prasenajit; "Romakam" may be the Byzantine Empire; the "naked ones" would be the Niganthas. In Tibetan, the country named "Tho-gar" "Thod-kar" corresponds to Tokharistan (ancient Bactria).
ADAM (A Database of Anti-Microbial peptides) Archived 2015-06-17 at the Wayback Machine at ntou.edu.tw AntiFP Prediction of antifungal peptides AntiMPmod Prediction of antimicrobial potential of modified peptides Antimicrobial+Cationic+Peptides at the U.S. National Library of Medicine Medical Subject Headings (MeSH) AntiTbPred Prediction of anti-tuberculosis peptides Antimicrobial Peptide Database Archived 2011-07-20 at the Wayback Machine at University of Nebraska Medical Center Antimicrobial Peptide Scanner Deep Learning based AMP prediction server AntiTbPdb Anti Tubercular Peptide Database BioPD[link removed] at Peking University Health Science Center CAMP:Collection of Anti-Microbial Peptides at National Institute for Research in Reproductive Health (NIRRH) DBAASP - Database of Antimicrobial Activity and Structure of Peptides] LAMP at Fudan University PeptideLocator Prediction of functional peptides, including antimicrobial peptides, in a protein sequence PeptideRanker Bioactive peptide, including antimicrobial peptide, prediction modlAMP Python package for computational work with antimicrobial peptides, including sequence handling, -design, -prediction, descriptor calculation and plotting
In 2001, Nakai et al. reported the development of GCaMP1 as a Ca2+ probe with improved signal-to-noise ratio compared to previously developed fluorescent Ca2+ probes. The first transgenic mouse expressing GCaMP1 was reported in 2004. However, at 37 ˚C (physiological temperature in mammals), GCaMP1 did not fold stably or fluoresce, limiting its potential use as a calcium indicator in vivo. In 2006, Tallini et al. subsequently reported the improvement of GCaMP1 to GCaMP2, which exhibited brighter fluorescence than GCaMP1 and greater stability at mammalian body temperatures. Tallini et al. expressed GCaMP2 in cardiomyocytes in mouse embryos to perform the first in vivo GCaMP imaging of Ca2+ in mammals. Further modifications of GCaMP, including GCaMP3, GCaMP5, GCaMP6, and jGCaMP7, have been developed to progressively improve the signal, sensitivity, and dynamic range of Ca2+ detection, with recent versions exhibiting fluorescence similar to native GFP.
D-Ribose-L-cysteine was developed by Herbert T. Nagasawa, a medicinal chemist formerly affiliated with the United States Department of Veterans Affairs and the University of Minnesota, whose research focused on sulfur amino acid metabolism and hepatic toxicology. The compound and its use as a glutathione-enhancing agent are protected by multiple patents, including United States Patent US 9,173,917 B2, assigned to Max International and the U.S. Department of Veterans Affairs. D-Ribose-L-cysteine has since been incorporated into dietary supplement formulations marketed by Max International, Inc. and LiveMax, LLC.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.
It acts as an agonist at the growth hormone secretagogue receptor, also known as the ghrelin receptor. Binding at pituitary somatotroph cells promotes growth hormone release.
Early studies report weaker effects on cortisol, prolactin, and appetite than compounds such as GHRP-6. The size of that difference in humans is not firmly established.
It is reported as the percentage of total peak area in a reversed-phase chromatogram. That number does not reflect water content, residual solvents, or counterions. The actual peptide content is therefore lower than the stated purity figure suggests.